Literature DB >> 28630312

Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma.

Ranran Wang1, Xing-Jun Cao2, Katarzyna Kulej2, Wei Liu1, Tongcui Ma1, Margo MacDonald1, Cheng-Ming Chiang3,4,5, Benjamin A Garcia2, Jianxin You6.   

Abstract

The epigenetic reader BRD4 plays a vital role in transcriptional regulation, cellular growth control, and cell-cycle progression. Dysregulation of BRD4 function has been implicated in the pathogenesis of a wide range of cancers. However, how BRD4 is regulated to maintain its normal function in healthy cells and how alteration of this process leads to cancer remain poorly understood. In this study, we discovered that BRD4 is hyperphosphorylated in NUT midline carcinoma and identified CDK9 as a potential kinase mediating BRD4 hyperphosphorylation. Disruption of BRD4 hyperphosphorylation using both chemical and molecular inhibitors led to the repression of BRD4 downstream oncogenes and abrogation of cellular transformation. BRD4 hyperphosphorylation is also observed in other cancers displaying enhanced BRD4 oncogenic activity. Our study revealed a mechanism that may regulate BRD4 biological function through phosphorylation, which, when dysregulated, could lead to oncogenesis. Our finding points to strategies to target the aberrant BRD4 signaling specifically for cancer intervention.

Entities:  

Keywords:  CDK9; NUT midline carcinoma; bromodomain-containing protein 4; cancer; cellular transformation

Mesh:

Substances:

Year:  2017        PMID: 28630312      PMCID: PMC5502625          DOI: 10.1073/pnas.1703071114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  73 in total

1.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.

Authors:  Nicolas Reynoird; Brian E Schwartz; Manuela Delvecchio; Karin Sadoul; David Meyers; Chandrani Mukherjee; Cécile Caron; Hiroshi Kimura; Sophie Rousseaux; Philip A Cole; Daniel Panne; Christopher A French; Saadi Khochbin
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

2.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

3.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

4.  MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.

Authors:  Adlai R Grayson; Erica M Walsh; Michael J Cameron; Jernej Godec; Todd Ashworth; Jessica M Ambrose; Alexandra B Aserlind; Hongfang Wang; Gerard Evan; Michael J Kluk; James E Bradner; Jon C Aster; Christopher A French
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

5.  Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

Authors:  M Andreeff; R Stone; J Michaeli; C W Young; W P Tong; H Sogoloff; T Ervin; D Kufe; R A Rifkind; P A Marks
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

6.  Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.

Authors:  Lisa M Nilsson; Lydia C Green; Somsundar Veppil Muralidharan; Dağsu Demir; Martin Welin; Joydeep Bhadury; Derek T Logan; Björn Walse; Jonas A Nilsson
Journal:  Cancer Res       Date:  2016-03-03       Impact factor: 12.701

Review 7.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

8.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

9.  A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.

Authors:  Xiao-ning Gao; Ji Lin; Qiao-yang Ning; Li Gao; Yu-shi Yao; Ji-hao Zhou; Yong-hui Li; Li-li Wang; Li Yu
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

10.  KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns.

Authors:  Yung-Hao Wong; Tzong-Yi Lee; Han-Kuen Liang; Chia-Mao Huang; Ting-Yuan Wang; Yi-Huan Yang; Chia-Huei Chu; Hsien-Da Huang; Ming-Tat Ko; Jenn-Kang Hwang
Journal:  Nucleic Acids Res       Date:  2007-05-21       Impact factor: 16.971

View more
  18 in total

1.  BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.

Authors:  Brandon Leonard; Toni M Brand; Rachel A O'Keefe; Eliot D Lee; Yan Zeng; Jacquelyn D Kemmer; Hua Li; Jennifer R Grandis; Neil E Bhola
Journal:  Cancer Res       Date:  2018-05-23       Impact factor: 12.701

2.  Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors.

Authors:  Ryan D Martin; Yalin Sun; Sarah MacKinnon; Luca Cuccia; Viviane Pagé; Terence E Hébert; Jason C Tanny
Journal:  Mol Cell Biol       Date:  2020-06-29       Impact factor: 4.272

Review 3.  Targeting cyclin-dependent kinase 9 in cancer therapy.

Authors:  Yi-Li Shen; Yan-Mao Wang; Ya-Xin Zhang; Shen-Jie Ma; Le-He Yang; Cheng-Guang Zhao; Xiao-Ying Huang
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169

4.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

5.  BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice.

Authors:  Gaelle Auguste; Leila Rouhi; Scot J Matkovich; Cristian Coarfa; Matthew J Robertson; Grazyna Czernuszewicz; Priyatansh Gurha; Ali J Marian
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

6.  Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis.

Authors:  Ranran Wang; June F Yang; Flora Ho; Erle S Robertson; Jianxin You
Journal:  Cancers (Basel)       Date:  2020-06-20       Impact factor: 6.639

Review 7.  A 47-year-old woman with nuclear protein in testis midline carcinoma masquerading as a sinus infection: a case report and review of the literature.

Authors:  Safwan K Elkhatib; Beth K Neilsen; Richard L Sleightholm; Michael J Baine; Weining Zhen
Journal:  J Med Case Rep       Date:  2019-03-11

8.  Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma.

Authors:  Yaping Wu; Yanling Wang; Pengfei Diao; Wei Zhang; Jin Li; Han Ge; Yue Song; Zhongwu Li; Dongmiao Wang; Laikui Liu; Hongbing Jiang; Jie Cheng
Journal:  Theranostics       Date:  2019-02-28       Impact factor: 11.556

Review 9.  An Overview of Molecular Mechanism, Clinicopathological Factors, and Treatment in NUT Carcinoma.

Authors:  Qian W Huang; Li J He; Shuang Zheng; Tao Liu; Bei N Peng
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411

10.  Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.

Authors:  Wenyu Wang; Yen-An Tang; Qian Xiao; Wee Chyan Lee; Bing Cheng; Zhitong Niu; Gokce Oguz; Min Feng; Puay Leng Lee; Baojie Li; Zi-Huan Yang; Yu-Feng Chen; Ping Lan; Xiao-Jian Wu; Qiang Yu
Journal:  Nat Commun       Date:  2021-07-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.